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ABSTRACT
The phylogenetic enlargement of cerebral cortex culmin-
ating in the human brain imposed greater communication
needs that have been met by the massive expansion of WM
(white matter). Damage to WM alters brain function, and
numerous neurological diseases feature WM involvement.
In the current review, we discuss the major features of WM,
the contributions of WM compromise to brain patho-
physiology, and some of the mechanisms mediating WM
injury. We will emphasize the newly appreciated import-
ance of neurotransmitter signalling in WM, particularly
glutamate and ATP signalling, to understanding both
normal and abnormal brain functions. A deeper under-
standing of the mechanisms leading to WM damage will
generate much-needed insights for developing therapies
for acute and chronic diseases with WM involvement.
Key words: demyelination, excitotoxicity, human brain,
ischaemia, multiple sclerosis, spinal cord injury, stroke.
INTRODUCTION
WM (white matter), as opposed to GM (grey matter),
exclusively contains axons and their glial cell partners; absent
from WM are neuronal cell bodies, dendrites and conven-
tional synaptic structures. Glial cells in WM are unique. WM
astrocytes have especially long, highly discrete processes,
which have led to their designation as ‘fibrous’ astrocytes
(Kettenmann and Ransom, 2005). Oligodendrocytes, which
make and sustain myelin, predominate in WM, although their
density varies regionally as a function of the percentage of
axons that are myelinated in a given tract (e.g. 100% in optic
nerve to fewer in corpus callosum). Myelin consists of tightly
wrapped oligodendrocytic processes that surround larger
diameter axons and mediate saltatory action potential
conduction, which increases conduction velocity by at least
50-fold compared with unmyelinated fibres of similar
diameter.
WM comprises approximately one-half of the forebrain
volume of humans, a 3- to 4-fold increase over rodents, the
animals most often used in neuroscience research (Zhang and
Sejnowski, 2000; Hamner et al., 2011). The very low relative
volume of WM in rodents has contributed to serious
misunderstanding regarding the pathophysiology of stroke,
and perhaps other diseases, and has slowed progress to
effective therapy (Ransom and Baltan, 2009).
WM damage implies primary or secondary disruption of
axon function causing disturbance of signal transmission and
altered neurological functions that can range from acute,
devastating loss of motor function (Hamner et al., 2011) to
subtle changes in motor and sensory performance or
cognitive impairment (Filley, 2001; Desmond, 2002). The
subject is broad and in this review, we focus primarily on
mechanisms by which the neurotransmitters glutamate and
ATP support WM function in health or cause damage to it
under pathological conditions.
NEUROTRANSMITTER SIGNALLING IN WM
Glial cells are endowed with the molecular machinery to
communicate with neurons (and among themselves) using
neurotransmitters. These mechanisms of cell-to-cell com-
munication are not without controversy (Agulhon et al.,
2010; Perea and Araque, 2010), but appear to participate in
synaptic transmission and neuronal–glial networking in a
manner that contributes to brain function (Verkhratsky,
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asnneuro.org / Volume 4 (2) / art:e00079 892010). The signalling capacity of glial cells is not confined to
GM. Glia in WM have similar attributes, although in the
absence of conventional neuronal synapses their functional
significance is less clear (Stys, 2005; Constantinou and Fern,
2009; Butt, 2011; Matute, 2011). Intriguingly, one way that
glial cells communicate in WM is a form of signalling that re-
sembles ’classical’ synapses between neurons (Kukley et al.,
2007; Ziskin et al., 2007; Etxeberria et al., 2010). Adding to
this emerging scenario, a new type of chemical synapse
between axons and myelin has recently been proposed (Stys,
2011). This section summarizes current knowledge on the
mechanisms of WM communication through neurotransmit-
ters emphasizing glutamate and ATP signalling, which has
been thoroughly studied in WM. In addition, WM cells are
also endowed with an array of GABA (c-aminobutyric acid)-A,
nicotinic, and glycine receptors whose physiological signifi-
cance remains to be elucidated (Domingues et al., 2010).
Glutamate signalling in glia and axons
Glutamate signalling occurs via GluRs (glutamate receptors)
and is terminated by GluTs (glutamate transporters).
Glutamate activates ionotropic and metabotropic receptors
that are expressed in glial cells in both GM and WM (for
recent reviews, see Verkhratsky and Kirchhoff, 2007; Bakiri
et al., 2009; Matute, 2011). In particular, cells of the
oligodendrocyte lineage express functional AMPA (a-amino-
3-hydroxy-5-methylisoxazole-4-propionic acid) and kainate
type receptors throughout a wide range of developmental
stages and species, including humans (Matute et al., 2007a).
In addition, immature and mature oligodendrocytes express
NMDA (N-methyl-D-aspartate) receptors, which can be
activated during injury in very young animals (Ka ´rado ´ttir
et al. 2005; Salter and Fern, 2005; Micu et al. 2006); the
situation in adult animals appears to be more complicated
(Baltan et al., 2008). Moreover, oligodendrocytes also express
receptors from all three groups of metabotropic GluRs;
however, the expression level of these receptors is devel-
opmentally regulated and is very low in mature cells of this
lineage (Deng et al. 2004).
Glutamate uptake from the extracellular space is con-
ducted by specific GluTs, and is essential for the shaping of
excitatory postsynaptic currents and for the prevention of ex-
citotoxic death due to over stimulation of GluRs (Rothstein
et al. 1996). At least five GluTs have been cloned (Danbolt,
2001). Of these, GLT-1 (glutamate transporter 1, also known
as EAAT2) exhibits the highest level of adult expression,
overwhelmingly in astrocytes, and it is responsible for most
glutamate transport (Danbolt, 2001). GluTs are also expressed
by oligodendrocytes, although their expression has been less
well characterized in these cells than in astrocytes. The main
transporter expressed by oligodendrocytes is GLAST (glutam-
ate aspartate transporter; also known as EAAT1). The neuronal
transporter, termed EAAC1 (excitatory amino acid carrier 1 or
EAAT3), is present in a subpopulation of adult oligodendro-
cyte progenitor cells (Domercq et al. 1999). It appears that all
macroglial cells differentially express the three major GluTs
present in the CNS (central nervous system). These transpor-
ters maintain basal levels of extracellular glutamate in the
range of 1–2 mM and prevent over-activation of GluRs
under physiological conditions. In turn, GluTs can contribute
to glutamate release in WM by reversing Na
+-dependent
glutamate transport during depolarization (Domercq et al.,
1999; Li et al., 1999; but see Longuemare et al., 1999). While
glutamate transport in GM is predominately mediated by
astrocytes (e.g. Anderson and Swanson, 2000) there is less
information about this function in WM.
In addition, glutamate homoeostasis is also regulated by
system xc
2, a membrane-bound, Cl
2-dependent, Na
+-inde-
pendent antiporter that mediates the cellular uptake of
cystine in a 1:1 exchange for glutamate (Conrad and Sato,
2012). The cystine/glutamate antiporter is the main neuronal
source of cystine, which is intracellularly converted to
cysteine, the rate-limiting substrate in glutathione synthesis.
System xc
2 is vital for antioxidant defence; its expression is
rapidly up-regulated under oxidative stress, although its en-
hanced function increases extracellular glutamate levels and
may cause excitotoxicity (Conrad and Sato, 2012). Notably,
system xc
2 is expressed by astrocytes, and by resting and
activated microglia (Domercq et al., 2007; Pampliega et al.,
2011; Had-Aissouni 2012).
Axons are also endowed with GluRs and GluTs. Native
AMPA receptors in axons are formed by the GluR4 subunit
and kainate receptors are composed of at least GluR5 and
GluR6 subunits, which in all instances are located in the
internodes (Ouardouz et al., 2009a, b). In turn, the major GluT
expressed by axons is GLT-1, although significant levels of
GLAST are also present (Li et al., 1999). These results must be
carefully interpreted because the mere presence of molecules
of interest does not guarantee functional or pathophysiolo-
gical significance. In this regard, our understanding of WM is
perhaps a decade behind GM.
Axon AMPA receptors in spinal axons are weakly permeable
to Ca
2+, the entry of which releases additional Ca
2+ from the
axoplasmic reticulum by opening intracellular Ca
2+ channels
known as ryanodine receptors (Ouardouz et al., 2009a). In
contrast, axonal kainate receptors with the GluR5 subunit are
coupled to phospholipase C activation (Ouardouz et al.,
2009a). In addition, activation of kainate receptors with the
GluR6 subunit induces a small amount of Ca
2+ entry that sti-
mulates NOS (nitric oxide synthase), as well as a local
depolarization that activates L-type Ca
2+ channels, and
subsequently ryanodine receptors, in the axoplasmic reticu-
lum (Ouardouz et al., 2009b). The functional significance of
these signalling mechanisms by GluRs in axons is unclear,
although they may serve to amplify axonal Ca
2+ signals that
appear to be weak because of the limited quantity of cation
available in the narrow space (Ouardouz et al., 2009b).
Notably, local activation of axonal AMPA/kainate receptors
by glutamate released from periaxonal astrocytes may
increase the width of action potentials while they travel
down axons (Sasaki et al., 2011). In turn, the broadened
C. Matute and B.R. Ransom
90 E 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.action potential triggers larger calcium elevations in
presynaptic boutons and facilitates synaptic transmission to
postsynaptic neurons (Sasaki et al., 2011). This glial-mediated
action potential modification might enable axonal computa-
tion through the geometry of axon wiring.
Glutamate signalling in oligodendrocytes is also relevant to
myelination. Action potentials travelling along axons can
release glutamate in a vesicular manner, which promotes
myelin induction by stimulating the formation of cholesterol-
rich signalling domains between oligodendrocytes and axons
and increasing the local synthesis of major myelin proteins
(Wake et al., 2011).
Together, these observations illustrate that WM glia and
axons possess all the major components of the molecular
machinery for glutamate signalling.
Purinergic signalling in WM glia and axons
The main endogenous agonists of the purinergic system are
adenosine and ATP, which activate P1 and P2 purinergic re-
ceptors respectively. These receptors are widely distributed
throughout the CNS, as well as in other organs. The phy-
siological and pathophysiological characteristics of P1 and P2
purinergic receptors have been extensively reviewed
(Verkhratsky et al., 2009; Burnstock et al., 2011; Matute
and Cavaliere, 2011). In this section, we highlight some major
properties of P1 and P2 receptors in glia that are relevant to
both health and CNS disease.
P1 receptors
Adenosine is a neuromodulator that typically restrains
neuronal excitability by acting at P1 receptors. P1 adenosine
receptors are metabotropic receptors and are classified as A1,
A2a,A 2b and A3 receptors. A1 and A3 receptors can inhibit
adenylate cyclase or activate phospholipase C, while A2a and
A2b receptors activate cAMP production (Fredholm et al.,
2001). Extracellular adenosine levels are directly related to
the degree of neural activity and to the catabolism of
released ATP by ectonucleotidases. In turn, adenosine can also
be released (especially in stressful conditions) through bi-
directional and non-concentrative nucleoside transporters,
whose main function is to remove extracellular adenosine
(Malva et al., 2003). Intracellular adenosine levels are largely
controlled by adenosine kinase, which is part of a substrate
cycle between adenosine and AMP. Small changes in
adenosine kinase activity rapidly translate into major changes
in adenosine (Boison et al., 2010). This dual role suggests that
adenosine acts as a physiological neuromodulator and as a
homoeostatic regulator in pathology.
All four adenosine receptors are present in astrocytes. Their
activation results in various direct effects, including hyper-
polarization, calcium release from internal stores and calcium
entry, as well as modulation of the amplitude and/or kinetics
of calcium transients initiated by the activation of metabo-
tropic GluRs, muscarinic receptors and P2Y receptors
(Verkhratsky et al., 2009). A serious limitation of these
functional studies is that they are mostly restricted to in vitro
cultures of astrocytes and do not provide evidence of the
significance of P1 receptors in vivo. On balance, there is now
strong evidence that astrocytes play a key role in the control
of extracellular adenosine levels (Boison et al., 2010).
Oligodendrocytes and their precursors also express all four
types of P1 receptors, as shown by PCR in culture and in
freshly isolated cells (Stevens et al., 2002). Activation of P1
receptors in oligodendroglia, by direct application of
adenosine or by action potentials in nearby neurons, induces
transient calcium increase. Interestingly, adenosine acts as a
potent neuronal–glial transmitter to inhibit the proliferation
of oligodendrocyte precursor cells, stimulate differentiation,
and promote myelin formation (Stevens et al., 2002). Thus,
adenosine and ATP released from axons mediate axon-to-
oligodendrocyte signalling during development (Fields, 2011).
Microglial cells express ectonucleotidase isoforms, as well
as all types of adenosine receptors that endow microglia with
the capacity to sense released and ambient ATP (Fa ¨rber and
Kettenmann, 2006). Activation of A1 and A2 receptors
promotes microglial proliferation, while A3 receptors mediate
the phosphorylation of ERK1/2 (extracellular-signal-regulated
kinase 1/2). In turn, the activation of A2a receptors in mi-
croglia can release neurotrophic factors in neuroprotection
and regulate the synthesis of PGE2 (prostaglandin E2;
Fa ¨rber and Kettenmann, 2006).
Central axonal conduction may be modulated by adenosine
(Sasaki et al., 2011). Specifically, A1 receptors are present on
corpus callosum axons and actively modulate axon physiology
by decreasing the compound action potential amplitude (Fern
et al., 1994; Swanson et al., 1998). Importantly, blockade of
A1 receptors in axon shafts increases the width of action
potentials, an effect that facilitates synaptic transmission to
distant postsynaptic neurons (Sasaki et al., 2011).
P2 receptors
Glial cells also express a heterogeneous repertoire of ATP
receptors, including an ample variety of ionotropic (P2X) and
metabotropic (P2Y) purinergic receptor subtypes (Verkhratsky
et al., 2009; Butt, 2011). ATP-gated P2X channels are formed
by P2X1– P2X7 subunits, and are markedly permeable to Ca
2+.
Activation of P2X1 and P2X1 results in fast, rapidly de-
sensitizing currents. In contrast, P2X2, P2X4 and P2X7 are
capable of a conformational change that results in larger
pore diameter after prolonged exposure to ATP.
Astrocytes express most of the P2X and P2Y receptor sub-
types, whose activation mediates signalling through the
astrocytic syncytium (James and Butt, 2002; Fields and
Burnstock, 2006). In particular, activation of P2X7 receptors
in astrocytesincreases[Ca
2+]i and causes therelease ofpurines.
Optic nerve astrocytes also express a variety of P2X receptors,
which are highly permeable to Ca
2+, and P2Y receptors, which
mobilize Ca
2+ from intracellular stores (James and Butt, 2002),
as reported in GM astrocytes.
White matter vulnerability
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91Cells of the oligodendrocyte lineage are also endowed with
P2X and P2Y receptors, which can act as mediators of axo-
oligodendroglial communication related to myelination
control (Fields, 2011). In particular, ATP induces a rise in cy-
tosolic Ca
2+ in oligodendrocytes by activating ionotropic P2X7
receptors (James and Butt, 2002; Matute et al., 2007b) and
metabotropic P2Y receptors (Kirischuk et al., 1995; James
and Butt, 2002). Moreover, mature oligodendrocytes of the
optic nerve express most of the P2X receptor subtypes, with
the P2X7 subtype being the most predominant; it is located
in the oligodendrocyte soma and the myelin sheath (James
and Butt, 2002; Matute et al., 2007b). P2X receptors with
higher affinity may be activated by ATP released during
axonal electrical activity and/or from astrocytes (Butt, 2011).
In contrast, the functional significance of lower affinity P2X7
receptors in oligodendrocytes is not known, since unusually
high ATP concentrations are needed in the extracellular space
to activate them. However in pathological conditions, ATP
levels may rise sufficiently to stimulate P2X7 receptors upon
tissue damage, and therefore they may be relevant to acute
and chronic WM injury (Wang et al., 2004; Matute et al.,
2007b). Moreover, oligodendrocyte progenitor cells express
the uracil nucleotide/cysteinyl leukotriene receptor, which
modulates oligodendrocyte differentiation and acts as a
sensor for acute and chronic damage (Boda et al., 2011).
Microglia express several P2X and P2Y receptors that act as
sensors of astrocyte activity and trigger cytokine release
(Fields and Burnstock, 2006; Fa ¨rber and Kettenmann, 2006).
Major subtypes of purinergic receptors expressed by microglia
include P2X4, P2X7, P2Y6 and P2Y12 receptors (Burnstock et al.,
2011). Depending on the amount of ATP released during brain
damage, microglia can release factors that favour neuropro-
tection, such as plasminogen and IL-6 (interleukin-6), or that
are detrimental to neuronal survival. In particular, microglial
P2X7 receptors drive microglial activation and proliferation
(Monif et al., 2009) and are functionally linked to the release
of several substances that influence pathological processes
and promote neurodegeneration, including pro-inflammatory
cytokines such as IL-1b (Fa ¨rber and Kettenmann, 2006).
Moreover, ATP is a potent immunomodulator that controls
microglial recruitment and activation (Davalos et al., 2005;
Nimmerjahn et al., 2005) by acting at P2Y12 receptors to
induce microglial chemotaxis at early stages of the response
to local CNS injury (Haynes et al., 2006).
Structural and functional properties of WM
synapses
The old dogma stated that chemical synaptic specializations
occurred exclusively between neurons. This idea was
challenged by the discovery of functional glutamatergic
and GABAergic synapses between axon terminals and NG2
(nerve/glial antigen 2)-expressing cells in the hippocampus
(Bergles et al., 2000; Lin and Bergles, 2004). The character of
these NG2-expressing cells has been difficult to elucidate
fully. Under certain conditions, they are able to differentiate
into oligodendrocytes; however, they also have properties
reminiscent of astrocytes. Their function(s), beyond repre-
senting a progenitor cell pool for oligodendrocytes, is not
understood. NG2 cells in WM also make occasional synapses
with unmyelinated axons in an en passant fashion (Kukley
et al., 2007; Ziskin et al., 2007; Etxeberria et al., 2010;
reviewed in Mangin and Gallo, 2011). Thus, action potentials
induce vesicular release of glutamate from unmyelinated
axons in the corpus callosum that activate NG2 AMPA
receptors during development and in the mature brain. To
add to this complex mosaic of glutamate signals, axonal–glial
synapses may also be modulated by the vesicular release of
glutamate from astrocytes, as observed in classical inter-
neuronal synapses (Volterra and Meldolesi, 2005).
Activation of glutamatergic and GABAergic synapses in
NG2 cells induces Ca
2+ entry directly through the receptor
channel or indirectly through the activation of voltage-
dependent calcium channels and/or the reversal of NCX (Na
+/
Ca
2+ exchanger) (reviewed by Mangin and Gallo, 2011).
Neuron-NG2 synapses are formed during spontaneous
remyelination after demyelination, a feature suggesting that
they may act in the early steps of the myelination/
remyelination process (Etxeberria et al., 2010). This possibility
is supported by the fact that NG2 cells lose their synapses as
they differentiate into myelinating oligodendrocytes (Kukley
et al., 2010). Therefore it is plausible that glutamatergic
synapses inhibit NG2 cell proliferation in an activity-
dependent manner (Mangin and Gallo, 2011). Indeed,
glutamate is known to inhibit NG2 cell proliferation, increase
their migration speed, and inhibit their ability to differentiate
into oligodendrocytes in vitro (reviewed in Mangin and Gallo,
2011).
The axo-myelin synapse
Mature CNS myelin sheaths express various AMPA and kainate
receptor subunits, as well as functional NMDA receptors
(reviewedin Stys, 2011).Curiously, these NMDA receptors have
unique properties: they lack NR2A,B subunits, seem to have
NR2C,D instead, and some are NR1/NR3A ’glycine-only’
receptors; and they display reduced Ca
2+ permeability and
Mg
2+ sensitivity. In turn, myelin also expresses purinergic
P2X7-type receptors (Matute, 2011). Interestingly, immuno-
gold labelling and electron microscopic examination revealed
that both NMDA and P2X7 receptors are preferentially
localized at the inner and outer myelin loops.
The presence of neurotransmitter receptors in the inner
myelin loop led to the hypothesis that myelin is the target for
neurotransmission across a putative axo-myelin synapse, with
the internodal axon cylinder acting as the presynaptic element
and the periaxonal space equivalent to the synaptic cleft (Stys,
2011). Indeed, vesicular release of transmitter is apparent in
unmyelinated axon-to-NG2 cell synapses (see above), and
premyelinated central axons contain glutamate-laden vesicles
and the machinery for vesicular release (Alix et al., 2008);
however, it is unclear whether this mechanism persists after
C. Matute and B.R. Ransom
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uptake systems in the axon membrane, particularly at the
nodes of Ranvier, as well as in the myelin (reviewed in Stys,
2011).
Together, these findings suggest that communication
between axons and myelin shares many features of conven-
tional chemical synapses found in GM. This axon–myelin
interplay may provide a mechanism by which myelin-
supporting oligodendrocytes up-regulate the transfer of
energy metabolites to fuel a more electrically active fibre
(Stys, 2011). Such a system might seem at odds with evidence
that glycogen (which is contained exclusively in astrocytes)
supports axons during intense activity or in the temporary
absence of glucose. In fact, astrocytes and oligodendrocytes
form gap junctions, and may cooperate to provide a ‘supply
line’ for the delivery of energy substrate to axons, whether
they are myelinated or not. Although this hypothesis needs
further experimental support, it provides novel ideas that may
be relevant to myelination and WM damage.
Pathophysiology of neurotransmitter signalling
in WM
We have outlined above that WM glia and axons communicate
through neurotransmitters in a manner that shares many of
the features common to classical chemical synapses. In this
section, we will discuss how neurotransmitter signalling,
particularly glutamate and/or ATP signalling pathways, may
initiate and/or contribute to glial cell death and axonal
damage. Then, we will describe current evidence illustrating its
relevance to WM pathology in CNS disorders (Table 1).
Emerging evidence indicates that nicotinic receptors and
adrenoreceptors may also be involved in WM injury
(Constantinou and Fern, 2009; Nikolaeva et al., 2009).
However, the potential relevance of those findings requires
further assessment.
Glutamate excitotoxicity in WM
The term excitotoxicity was coined more than 50 years ago,
and refers to neuronal damage by excessive activation of
glutamate ionotropic receptors. Although the concept was
created to explain GM injury, especially during stroke, it is
also highly relevant to WM (Ransom and Baltan, 2009), where
receptor-mediated glutamate toxicity is clearly involved in
certain pathological conditions.
Over-activation of AMPA and kainate receptors causes
oligodendrocyte death and primary and/or secondary myelin
destruction (Matute, 2011). The influx of Ca
2+ upon receptor
activation and the ensuing accumulation of Ca
2+ within
mitochondria are central to this process. These events lead
to mitochondrial depolarization, increased production of
radical oxygen species and the release of pro-apoptotic
factors, which in turn activate caspase-dependent and
-independent oligodendrocyte death (Sa ´nchez-Go ´mez et al.,
2003). Detailed studies of oligodendrocyte excitotoxicity have
shown that Bax and calpain are essential intermediaries
(Sa ´nchez-Go ´mez et al., 2011), and that Ca
2+-induced calcium
release through ryanodine receptors also contributes to
mitochondrial dysfunction and ER (endoplasmic reticulum)
stress (Ruiz et al, 2010). However, the mechanisms triggered
by NMDA receptor-mediated insults to oligodendrocytes have
not yet been studied in detail.
The direct inhibition of glutamate uptake in axonal tracts
leads to oligodendroglial loss, massive demyelination, and
severe axonaldamage(Domercq etal.,2005).Other factorsthat
may contribute to perturbing glutamate homoeostasis and
cause WM damage include: altered activity of the glutamate-
producing enzyme glutaminase in activated macrophages/
microglia in close proximity to dystrophic axons (Werner et al.,
2001); and reducedexpression ofthe GluTs, GLAST and GLT-1 in
oligodendrocytes as a consequence of enhanced exposure to
the pro-inflammatory cytokine TNFa (tumour necrosis factor a)
(Pitt et al., 2003) and oxidative stress (Domercq et al., 2007).
Moreover, activated microglia increase their own expression of
xCT (glutamate–cystine exchange transporter), which contri-
butes further to increasing glutamate levels and glutamate
toxicity (Domercq et al., 2007). In turn, excessive activation of
internodal axonal GluRs may induce the release of substantial
amounts of calcium from axoplasmic ER and activate calcium-
dependent enzymes that ultimately ignite the collapse of the
axon (Stirling and Stys, 2010).
ATP excitotoxicity in WM
Purinergic signalling is relevant to neuroinflammation
associated with neurodegenerative diseases. These patholo-
gies give rise to increased levels of extracellular adenine
nucleotides which, through the activation of a variety of cell
surface P2 purinergic receptors, influence the inflammatory
activities of responding immune cells. In particular, the P2X7
receptor potentiates the release of pro-inflammatory cyto-
kines (such as IL-1b) from microglia and induces cell death. In
addition, ATP originating from dying cells may act as part of a
secondary mechanism to aggravate the extent of ongoing
CNS damage. Accordingly, neuroprotective properties of
classical and novel selective and non-selective P2X7 receptor
antagonists have been observed in various cellular and animal
models of CNS disorders to which excessive inflammatory
activities contribute (reviewed in Friedle et al., 2010).
Similar to GM, WM is vulnerable to excessive ATP
signalling. Excess ATP is a potent endogenous toxin that
can directly kill oligodendrocytes by activating P2X7 receptors
(Matute et al., 2007b). ATP excitotoxicity in oligodendrocytes
is Ca
2+-dependent and induces cell death by apoptosis or
necrosis, depending on the intensity of the insult. In addition,
P2X7 receptor engagement activates several second messen-
ger and enzyme cascades. In macrophages/monocytes and
microglia, P2X7 receptor stimulation rapidly activates JNKs (c-
Jun N-terminal kinases) 1 and 2, ERKs and p38 MAPK
(mitogen-activated protein kinase) (reviewed in Skaper et al.,
2010). Transcription factors whose activation and nuclear
White matter vulnerability
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93translocation are associated with the expression of inflam-
matory genes [e.g. NF-kB (nuclear factor kB), NFAT (nuclear
factor of activated T-cells), CREB (cAMP-response-element-
binding protein) and AP-1 (activator protein 1)] are also
activated by P2X7 receptors in microglia. Moreover, stimu-
lation of P2X7 receptors involves Ca
2+ signalling and increases
protein tyrosine phosphorylation, ultimately leading to MAPK
pathway activation (reviewed in Skaper et al., 2010).
Stroke
Damage of central WM is a major cause of functional disability
in cerebrovascular disease; the majority of ischaemic strokes
involve both WM and GM (Goldberg and Ransom, 2003;
Hamner et al., 2011). Injury to WM as a consequence of
hypoxic-ischaemic injury occurs in PVL (periventricular
leukomalacia) in neonates and in stroke and cardiac arrest in
adults, as well as in vascular dementia in the aging brain. The
Table 1 White matter damage and dysfunction in CNS disorders and their animal models
EAE, experimental autoimmune encephalomyelitis; GluK2, kainate receptor subunit 2; KO, knockout; LPS, lipopolysaccharide; MCAO,
middle cerebral artery occlusion; nAChR, nicotinic acetylcholine receptor; OPC, oligodendrocyte precursor cell.
Disease Model/preparation Target/finding Mechanism References
Stroke Optic nerve NCX Blockade is protective Stys et al. (1992)
Cultured oligodendrocytes AMPA/kainate receptors Blockade prevents oligodendro
toxicity
Fern and Mo ¨ller
(2000)
Neonatal isolated optic
nerve
NMDA receptors Blockade prevents oligodendro
toxicity
Ka ´radottir et al.
(2005), Salter and
Fern (2005) and
Micu et al. (2006)
Older optic nerve AMPA/kainate receptors Blockade is protective Baltan et al. (2008)
NMDA receptors Blockade is NOT protective
Oligodendrocytes and
optic nerve
P2X7/pannexin-1 Receptor/hemichannel blockade Domercq et al.
(2010)
MCAO A2A receptors Blockade prevents oligodendro-
toxicity
Melani et al. (2009)
Perinatal ischaemia Hypoxia–ischaemia AMPA and NMDA
receptors
Blockade prevents oligodendro-
toxicity
Follett et al. (2004)
and Manning et al.
(2008)
Immature optic nerve AMPA and NMDA
receptors
Blockade prevents axon damage Alix and Fern (2009)
Hypoxia–ischaemia plus
LPS
Axon-OPC synapses Reduced oxidative stress Shen et al. (2012)
Hypoxia–ischaemia P2X7 receptors Blockade prevents oligodendro-
toxicity
Wang et al. (2009)
A1 receptor KO A1 receptors Reduced WM damage Turner et al. (2003)
Multiple sclerosis Acute and chronic EAE AMPA receptors Blockade protects myelin and
axons
Pitt et al. (2000),
Smith et al. (2000)
and Kanwar et al.
(2004)
Microglia activation in
optic nerve
AMPA/kainate receptors Blockade prevents oligodendro-
toxicity
Domercq et al.
(2007)
xCT Blockade prevents oligodendro-
toxicity
Oligodendrocytes and
optic nerve
Kainate receptors Blockade prevents complement
attack
Alberdi et al. (2006)
Chronic EAE in GluK2 KO GluK2 Reduced symptoms and damage Pe ´rez-Samartı ´n et al.
(2009)
Chronic EAE P2X7 receptors Blockade attenuates symptoms
and damage
Matute et al.
(2007b)
Human brain imaging Glutamate Altered homoeostais Srinivasan et al.
(2005)
Spinal cord injury Dorsal columns AMPA/kainate receptors Blockade attenuates damage Li and Stys (2000)
Contusion P2X7 receptors Blockade preserves function Peng et al. (2009)
Crush GLT-1 Lower expression increases
damage
Lepore et al. (2012)
AD Postmortem human brain Oligodendrocyte
apoptosis
Unknown Bronge (2002)
Imaging of human brain WM Oxidative stress damage Back et al. (2011)
Cultured oligodendrocytes Unknown b-amyloid oligotoxicity Xu et al. (2001)
Triple transgenic model Myelin alterations Unknown Desai et al. (2009)
Psychiatric disorders Postmortem brain schizo-
phrenia.
Reduction in
oligodendrocytes
Unknown Uranova et al. (2004)
Schizophrenia and bipolar
disorder
Reduced size of WM
tracts
Unknown McIntosh et al.
(2008) and Peters
et al. (2010)
Unknown Optic nerve Adrenoreceptors and
nAChR
Action potential block and glial
injury
Constantinou and
Fern (2009) and
Nikolaeva et al.
(2009)
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and animal studies suggest that WM can be damaged by even
brief ischaemia (Pantoni et al., 1996). Ischaemic insults
typically result in transmembrane ion gradient breakdown
and membrane depolarization, leading ultimately to toxic
intracellular Ca
2+ overload. The final stage is the activation of
Ca
2+-dependent enzymes (e.g. calpains, phospholipases and
other enzymes), resulting in irreversible damage of WM glia
and axons (Stys et al., 1992; Stys, 2004; Hamner et al., 2011).
These steps are surprisingly complex and much remains to be
learned.
Immature and differentiated oligodendrocytes, studied in
vitro, are very sensitive to transient oxygen and glucose
deprivation (Fern and Mo ¨ller, 2000). Both cell types can be
partially protected from irreversible ischaemic injury by
reducing extracellular Ca
2+ or by AMPA/kainate receptor
antagonists, but not by the blockade of other potential
sources of Ca
2+ influx, which suggests that Ca
2+ entry
through the receptor channel is sufficient to initiate cell
demise. Notably, simulated ischaemia induces an inward
current in oligodendrocytes that is partly mediated by NMDA
and AMPA/kainate receptors (Ka ´rado ´ttir et al., 2005). In
addition, Ca
2+ levels also increase in myelin itself during
ischaemia (an effect that is abolished by broad-spectrum
NMDA receptor antagonists), causing ultrastructural damage
to both axon cylinders and myelin (Micu et al., 2006).
Unfortunately, WM ischaemic injury in older animals
proceeds according to different rules. WM becomes intrins-
ically more vulnerable to ischaemia in older animals as the
mechanisms of injury change as a function of age (Baltan
et al., 2008). The removal of extracellular Ca
2+ or blockade of
Ca
2+ entry by reversing the NCX improves WM function in
young animals, but not in older animals (Baltan et al., 2008).
Indeed, Ca
2+-free conditions worsen recovery from ischaemic
insult in older animals, suggesting that Ca
2+ release from
intracellular Ca
2+ stores may become more critical during
ischaemia in aging WM. In turn, ischaemic WM injury in older
mice is predominately mediated by glutamate release through
reverse glutamate transport (probably from astrocytes) and
the ensuing activation of AMPA/kainate-type GluRs (Baltan
et al., 2008). Intriguingly, blockade of NMDA receptors
aggravates the outcome of ischaemia in older animals (Baltan
et al., 2008).
These findings clearly indicate that the mechanisms of
ischaemic damage to WM involve Ca
2+ dyshomoeostasis
induced by excessive glutamate signalling, which is age-
dependent. This important finding has profound consequences
for the development of optimized age-specific therapies for
the treatment of brain damage after stroke.
Intracellular levels of ATP decline and extracellular ATP is
elevated in GM (WM has yet to be evaluated) during cerebral
ischaemiaasaconsequenceofsecondaryanoxicdepolarization
(Frenguelli et al., 2007). ATP can be exocytosed in a Ca
2+-
dependent manner from synaptic vesicles, gap junction
hemichannels formed by connexins and pannexins, and other
ion channels (e.g. P2X7 receptors; Verkhratsky et al., 2009). In
turn, ischaemic insults can open pannexin hemichannels
and contribute to ATP release and post-anoxic depolarization
in cultured neurons (Thompson et al., 2006), as well as in
oligodendrocytes in vitro and in situ (Domercq et al., 2010),
although the results in neurons have not been confirmed in
acute slices (Madry et al., 2010). The rise in the extracellular
concentration of ATP during ischaemia is sufficient to activate
P2X7 receptors and kill neurons and oligodendrocytes, an event
thatispreventedbyblockadeofP2X7receptors(Domercqetal.,
2010; Arbeloa et al. 2012). In oligodendrocytes, in particular,
ischaemia triggers an inward current and cytosolic Ca
2+
overload, which are partially mediated by P2X7 receptors
(Domercq et al., 2010). P2X7 receptors in oligodendrocytes are
activated, at least in part, by ATP released through the opening
of pannexin channels during oxygen and glucose deprivation.
This process leads to mitochondrial depolarization and
oxidative stress culminating in oligodendrocytic death, which
is attenuated by P2X7 receptor antagonists, by the ATP-
degrading enzyme apyrase, and by blockers of pannexin
hemichannels (Domercq et al., 2010). These data indicate that
ATP is released during ischaemia, and that subsequent
activation of the P2X7 receptor is critical to WM demise
during stroke and in PVL.
Massive release of ATP during transient brain ischaemia
(and its subsequent degradation by ectonucleotidases) would
result in an increase in adenosine levels that may be sufficient
to activate P1 receptors and may have deleterious effects on
the CNS (Burnstock et al., 2011). The blockade of A2a
receptors protects from ischaemic damage to oligodendro-
cytes by reducing the activation of JNK p38 MAPK (Melani
et al., 2009). By contrast, adenosine can also be protective,
acting through a PKC (protein kinase C) pathway to provide a
form of autoprotection (Fern et al., 1994).
Perinatal ischaemia
PVL is the major neuropathological lesion in premature
infants, and involves focal WM necrosis and subsequent
hypomyelination. Its pathophysiology is multifactorial and
includes hypoxia–ischaemia-induced glutamate excitotoxi-
city, oxidative stress and inflammation (Volpe, 2009). Injury
to oligodendrocyte progenitors caused in part by glutamate
contributes to the pathogenesis of myelination disturbances
in PVL (Back and Rivkees, 2004). In the immature human
brain, the susceptibility of developing oligodendrocytes to
hypoxia–ischaemia correlates with their expression of GluRs
of the AMPA receptor subtypes in the immature human brain
(Talos et al., 2006), and systemic administration of AMPA
receptor antagonists attenuates injury in a rat model of PVL
(Follett et al., 2004). In addition, developing oligodendrocytes
also express NMDA receptors; their blockade with memantine
attenuates oligodendrocyte loss and prevents the long-term
reduction in cerebral mantle thickness that is observed in
experimental PVL (Manning et al., 2008). Intriguingly,
synapses between axons and oligodendroglial precursor cells
are quickly and profoundly damaged in PVL models, an
White matter vulnerability
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95observation that outlines the relevance of these synaptic
contacts to WM integrity during development (Shen et al.,
2012).
Ischaemic injury to axons is also a feature of PVL; it occurs
early in local and diffuse damage associated with this
pathology (Haynes et al, 2008). Interestingly, experimental
ischaemia in immature axons produces action potential
failure and focal breakdown of the axolemma of small
premyelinated axons at sites of contact with oligodendrocytic
processes, which are also disrupted (Alix and Fern, 2009).
Axon damage is prevented by NMDA and AMPA/kainate
receptor blockers, suggesting that GluR-mediated injury to
oligodendrocytic processes in contact with premyelinated
axons precedes disruption of the underlying axon (Alix and
Fern, 2009).
Perinatal ischaemia also triggers lethal activation of P2X7
receptors in oligodendrocyte precursors (Wang et al, 2009).
The oligodendrocyte precursors express P2X7 receptors; the
levels of these receptors are reduced after oxygen–glucose
deprivation in vitro and neonatal hypoxic–ischaemic injury,
suggesting a role for this receptor in the pathophysiology of
hypoxic–ischaemic brain injury (Wang et al, 2009). In
addition, A1 receptors may mediate some of the deleterious
effects of perinatal ischaemia on myelin and WM (Turner
et al., 2003).
Multiple sclerosis, a hallmark of WM damage
The major demyelinating disease of the CNS is multiple
sclerosis, which is the foremost disabling pathology among
young adults. Multiple sclerosis is a chronic, degenerative
disease of the CNS, which is characterized by focal lesions
with inflammation, demyelination, infiltration of immune
cells, oligodendroglial death and axonal degeneration (Prineas
et al, 2002). It is widely accepted that the aetiology of this
illness has autoimmune and inflammatory grounds, and that
a derailment of the immune system leads to cell- and
antibody-mediated attacks on myelin.
Both genetic and environmental factors contribute to
multiple sclerosis susceptibility (Zamvil and Steinman, 2003).
Among them, primary and/or secondary alterations in
glutamate signalling cause excitotoxicity, which in turn
contributes to multiple sclerosis pathology. Numerous studies
conducted in cellular and animal models of multiple sclerosis,
as well as in post-mortem brain and in patients, have
indicated that excitotoxicity mediated by Ca
2+-permeable
GluRs contributes to oligodendrocyte death, demyelination
and tissue damage in multiple sclerosis (Matute et al., 2001;
Srinivasan et al., 2005; Vallejo-Illarramendi et al., 2006). In
particular, EAE (experimental autoimmune encephalomyeli-
tis), a mouse disease model that exhibits the clinical and
pathological features of multiple sclerosis, is alleviated by
AMPA and kainate receptor antagonists (Pitt et al., 2000;
Smith et al., 2000). Indeed, mice deficient in the GluK2
(kainate receptor subunit 2) are less susceptible to EAE
(Pe ´rez-Samartı ´n et al., 2009). Remarkably, blockade of these
receptors in combination with anti-inflammatory agents is
effective even at an advanced stage of unremitting EAE, as
assessed by increased oligodendrocyte survival and remyeli-
nation, and corresponding decreased paralysis, inflammation,
CNS apoptosis and axonal damage (Kanwar et al. 2004).
Importantly, a recent genome-wide association screening
study identified associated alleles in AMPA receptor genes in
multiple sclerosis patients who exhibited the highest levels of
glutamate and brain volume loss (Baranzini et al., 2010).
These findings provided a novel quantitative endophenotype
that may help clarify the pathophysiology of the heterogen-
eity of clinical expression in multiple sclerosis. In addition,
another component of the genetic background linking
multiple sclerosis and the deregulation of glutamate
signalling may lie in a polymorphism in the Ca
2+-permeable
AMPA receptor subunit GluR3 (a subunit that is abundantly
expressed in oligodendrocytes), which is associated with a
subgroup of patients responding to IFNb (interferon b)
therapy in multiple sclerosis (Comabella et al., 2009). In
contrast, blockade of NMDA receptors with MK-801 does not
attenuate EAE symptoms (Matute, 2010), a finding that calls
into question the proposed relevance of NMDA receptors in
demyelinating diseases (Bakiri et al., 2009).
Glutamate levels are increased in the human brain
(Srinivasan et al., 2005) as a consequence of reduced
expression of the GluTs, GLAST and GLT-1 (Vallejo-
Illarramendi et al., 2006). Another mechanism accounting
for glutamate dyshomoeostasis is genetic variability in the
promoter of the major GluTs, GLT-1, which results in lower
transporter expression (Pampliega et al., 2008). In turn, up-
regulation of xCT in the monocyte–macrophage–microglia
lineage is associated with immune activation in both multiple
sclerosis and EAE (Pampliega et al., 2011).
Non-toxic glutamate concentrations also contribute to
demyelinating pathology by inducing oligodendrocyte death
by sensitizing oligodendrocytes to complement attack
(Alberdi et al., 2006). Intriguingly, complement toxicity is
induced by the activation of kainate, but not of AMPA,
NMDA or metabotropic GluRs. Oligodendrocytic death by
complement requires the formation of the membrane attack
complex, which in turn increases membrane conductance and
induces Ca
2+ overload and mitochondrial depolarization, as
well as an increase in the level of ROS (reactive oxygen
species; Alberdi et al., 2006). Sensitization by glutamate to
complement attack may initiate multiple sclerosis lesions
with massive oligodendrocyte apoptosis, as described earlier
(Barnett and Prineas, 2004).
As mentioned above, ATP signalling can trigger oligoden-
drocyte excitotoxicity through the activation of Ca
2+-permeable
P2X7 purinergic receptors expressed by these cells. Importantly,
sustainedactivationof P2X7 receptors invivocauseslesionsthat
are reminiscent of the major features of multiple sclerosis
plaques, and treatment of chronic EAE with P2X7 antagonists
reduces demyelination and ameliorates the associated neuro-
logical symptoms (Matute et al., 2007b). These results are in
a g r e e m e n tw i t hd a t ai nP 2 X 7 null mice showing that this
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2008), and at odds with earlier observations indicating that the
lackofP2X7receptors aggravates EAE (Chen and Brosnan,2006),
as well as our own unpublished data (A. Pe ´rez-Samartı ´n and C.
Matute). These apparent discrepancies may be caused by the
different strains and knockout mice used, and to solve this issue
will require the development of conditional P2X7 receptor
knockout mice that lack this transcript in specific glial cell
populations. In turn, the availability of these technical resources
would overcome the problem of interfering with the immune
system whereby P2X7 receptors may be relevant intermediaries
of the response to myelin antigens in EAE. In addition, P2X7 RNA
and protein levels are elevated in normal-appearing axon tracts
in multiple sclerosis patients, suggesting that oligodendroglial
signalling through P2X7 receptors is enhanced in multiple
sclerosis,which may render thiscell typemore vulnerabletoATP
dysregulation (Matute et al., 2007b). The increased expression of
P2X7 receptors in axontractsbeforelesionsare formed indicates
that this feature may constitute a risk factor associated with
newly forming lesions in multiple sclerosis; therefore this
receptor subunit may prove to be a diagnostic and/or prognostic
clinical biomarker for multiple sclerosis. In addition, blockade of
ATP P2X7 r e c e p t o r sp r o t e c t so l i g o d e n d r o c y t e sf r o md y i n g ;t h i s
property has therapeutic potential to halt the progression of
tissue damage in multiple sclerosis.
Other alterations of purinergic signalling in multiple
sclerosis include reduced expression of P2Y12 receptors in the
periphery of demyelinated lesions and increased expression of
uracil nucleotide/cysteinyl leukotriene receptor, a P2Y-like
receptor that is associated with defective myelination during
postnatal life (for review, see Burnstock et al., 2011).
Spinal cord injury
Traumatic injury to the CNS inevitably involves damage to
WM and causes primary mechanical destruction of glia and
axons. In addition, secondary impairment of tissue occurs as a
consequence of a prolonged pathological response involving
chronic inflammation, microglial activation and astroglial
scar formation. This prolonged response can ultimately result
in the development of a large cavity at the site of the lesion
and persistent functional deficits (Dumont et al., 2001).
Tissue destruction after traumatic brain injury leads to
the release of large amounts of glutamate, which cause
Ca
2+-dependent excitotoxic damage to WM astrocytes,
oligodendrocytes and myelin, but not to axons (Li and
Stys, 2000). Indeed, glutamate dysregulation is centrally
involved in the outcome following traumatic spinal cord
injury. After thoracic crush of the spinal cord, mice
heterozygous for the astrocytic GluTs, GLT-1 exhibit
attenuated recovery of hind limb motor function, increased
lesion size and reduced tissue sparing (Lepore et al., 2012).
These findings indicate that glutamate uptake by astrocytes
limits secondary damage after CNS traumatic injury, and
that promoting GluT expression and function may favour
post-lesion recovery.
Furthermore, ATP (which is also present at high levels in
the extracellular space after cell death) may cause Ca
2+-
dependent gliotoxicity, either directly by activating P2X
receptors, or after degradation to adenosine and subsequent
activation of P1 purinergic receptors (Verkhratsky et al, 2009).
However, the putative deleterious effects of P1 activation on
WM have not yet been demonstrated to occur after traumatic
injury.
Finally, spinal cord injury is associated with prolonged P2X7
receptor activation and ensuing neuronal excitotoxicity
(Wang et al., 2004). Strikingly, systemic administration of a
P2X7 antagonist that is able to cross the blood–brain barrier
ameliorates the motor behaviour of animals that had
previously been subjected to spinal cord contusion, indicating
that neuroprotection after injury can preserve function (Peng
et al., 2009). Oligodendrocyte preservation by P2X7 receptor
blockade in those experimental conditions may also be critical
to attenuate WM destruction and the ensuing motor and
sensory deficits.
AD (Alzheimer’s disease)
WM is altered in the aging brain, in AD as well as other
dementias (Back et al., 2011). A high percentage of AD
patients exhibit evidence of WM degeneration, as indicated
by severe apoptotic loss of oligodendrocytes (Bronge, 2002)
and free radical injury to myelin and axons (Back et al., 2011).
It is unclear whether this neuropathological feature is
primary or secondary to ongoing neuronal death. However,
it may be directly caused by the overload of b-amyloid
peptides characteristic of the AD brain, since these peptides
damage oligodendrocytes in vitro (Xu et al., 2001) and
increase their vulnerability to glutamate excitotoxicity (Pak
et al., 2003). In turn, injection of b-amyloid (1–42) into WM
causes axon disruption and myelin damage, as well as
oligodendrocyte loss and profound gliosis (Jantaratnotai
et al., 2003).
Transgenic models of AD also point to specific alterations
in WM. Mice expressing presenilin-1 mutants are more
susceptible to oligodendrocyte excitotoxicity and to demye-
linating agents, which result in learning and memory deficits
(Pak et al., 2003). These findings reveal that a specific
presenilin-1 mutation in oligodendrocytes can have det-
rimental effects leading to disease, and indicate that WM
damage may well contribute to cognitive dysfunction in AD.
In addition, triple-transgenic mice harbouring the human
Swedish mutant transgene of the amyloid precursor protein,
a presenilin knock-in mutation, and a tau P301L mutant
transgene, exhibit significant region-specific alterations in
myelination and in oligodendrocyte marker expression
profiles at time points preceding the appearance of
amyloid and tau pathology (Desai et al., 2009). These
findings in animal models of AD suggest that myelin and
oligodendrocyte defects in AD precede the onset of
symptoms and may be key players in the development
of this disease.
White matter vulnerability
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97WM dysfunction in psychiatric diseases
WM alterations have recently been detected in studies of
post-mortem brain tissue from psychiatric patients diagnosed
with schizophrenia, bipolar disorder and major depression.
Although these diseases are distinct in nature, they share
some WM distortions that may contribute to their patho-
physiology, including reduced oligodendrocyte number and
expression of myelin constituents (for recent reviews, see
Matute, 2010; Stys, 2011).
Neuropathological studies have revealed myelin defects
and oligodendrocyte alterations in brain tissue from schizo-
phrenic patients, correlating with the decreased expression of
myelin-related genes (McIntosh et al., 2005). For instance,
histological studies have demonstrated an abnormal distri-
bution and decreased density of oligodendrocytes in the
frontal regions of the cerebral cortex in schizophrenic
patients, as well as reduced cell numbers in certain cortical
layers (Uranova et al., 2004). The nature of the mechanisms
leading to hypomyelination and reduction of the oligoden-
drocyte population is unknown; however, it has been
proposed that hypomyelination may be caused by alterations
in Ca
2+ homoeostasis due to aberrant glutamate signalling in
these insidious diseases (Davis et al., 2003). Interestingly,
lithium (which is widely used to treat bipolar disorder)
regulates a number of components of signal transduction
machinery, including Ca
2+ homoeostasis, and has neuropro-
tective properties in experimental paradigms of excitotoxicity
(Bauer et al., 2003). Finally, diffusion tensor imaging suggests
that some axonal tracts are reduced in size, suggesting
vulnerable brain areas (McIntosh et al., 2008; Peters et al.,
2010) that may underlie changes in action potential
propagation caused by myelination pathways relevant to
psychiatric diseases (Whitford et al., 2010).
CONCLUSIONS
Primary and/or secondary WM damage occurs in acute and
chronic CNS diseases. Oligodendrocytes (the major cell type in
WM), the myelin sheath they elaborate and maintain and
axons are highly vulnerable to insults that initiate within the
CNS or in the immune system, such as multiple sclerosis.
The mechanisms triggering WM injury are only partially
understood. Oligodendrocytes are particularly sensitive to
alterations of glutamate and ATP homoeostasis, which may
kill these cells by excitotoxicity through over-activation of
both ionotropic GluRs and P2X7 purinoceptors. In addition, it
is conceivable that axons, which express AMPA and kainate
receptors, may undergo direct glutamate excitotoxicity. The
proper functioning of glutamate uptake is critical to prevent
glutamate-induced damage to WM, and drugs that regulate
the function and expression of GluTs have the potential to
attenuate glutamate insults. On the other hand, the control
of ATP release and degradation during acute and chronic
inflammation, as well as at early stages of post-ischaemic and
post-traumatic injury, may prove therapeutic. In addition,
other neurotransmitters, including acetylcholine and nora-
drenaline, can also be harmful to WM and consequently
relevant to disease (for a review, see Domingues et al, 2010).
A deeper knowledge about the mechanisms leading to WM
injury or demise mediated by glutamate and ATP receptors,
and by other neurotransmitters, will facilitate new phar-
macological strategies to treat CNS disorders in which WM is
severely compromised.
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